Researchers at Queen’s have developed a highly innovative new enzyme biomarker test that has the potential to indicate diseases and bacterial contamination saving time, money and possibly lives.
The test, developed by scientists at the Institute for Global Food Security (IGFS) at Queen’s, can detect enzyme markers of disease known as proteases in humans, animals and food products.
Proteases are crucial for microorganism growth and are responsible for the progression of many diseases.
Levels of these enzyme markers can be highly elevated in the urine of patients with diabetic kidney disease, or at the sites of infected wounds. Similarly, in cows, an elevation of proteases in their milk can reveal diseases such as bovine mastitis, a type of mammary gland infection. In food, proteases produced by bacteria contaminated in meat and dairy products can lead to rancidity, as well as decreased shelf life and quality.
Current protease detection methods are costly, time-consuming and are not always effective. Scientists at the IGFS have developed a nanosensor which has resulted in sensitive, fast and cost-effective protease detection in milk and urine.
Dr Claire McVey, Queen’s researcher and co-author on the study published in leading journal Nano Research, explained: “Not only is the test cheap to produce, but it can be used anywhere and is not reliant on laboratory conditions.
“Eliminating the need to carry out tests in a laboratory setting is life-changing. As well as being cost-effective, it means faster diagnosis.”
The gold-nanoparticle based nanosensor devised by Queen’s researchers indicates when proteases are present through a visible colour-change reaction. Gold nanoparticles are well known for their capability in speeding up the oxidization of a chemical called tetramethylbenzidine (TMB), visible through a vivid blue-colour formation.
When casein (a molecule present in milk) is added to gold nanoparticles, it surrounds the nanoparticles acting as a protective surface barrier. When TMB is introduced, the casein prevents the oxidization reaction meaning there is no or only a slight colour change.
Where proteases are present, they ‘eat’ the protective casein barrier, exposing the surface of the gold nanoparticles. In this instance, when TMB is added, the proteases have removed the casein meaning oxidization occurs quickly causing a fast change in colour.
Queen’s researcher Dr Cuong Cao, a Lecturer in Advanced Micro- and Nano-Diagnostics, and the lead academic on the study: “When we add TMB to the casein-covered gold nanoparticles, we can tell virtually instantly if proteases are present by whether or not the solution turns blue. Normally such testing takes much longer.”
Using this approach, proteases can be detected within 90 minutes without the need for complicated or expensive laboratory equipment.
In addition, the ‘ingredients’ for making the nanosensor are readily available and low cost. Gold nanoparticles can be produced in abundance, with little restriction on storage requirements, making it a durable and cheap substance.
The approach developed by the Queen’s researchers was tested on milk and urine but it could be adapted for a number of other applications. Dr Cao explained: “Using molecules other than casein to coat the surface has the potential to detect other types of enzyme biomarkers. For example, coating the nanoparticles with lipids could detect the lipase enzyme, which could help in the diagnosis of diseases such as pancreatitis.
“Following full validation of this test, we would like to explore how we could expand the application to detect a host of other diseases or contaminated foods.
“This new approach will enable the identification of enzyme biomarkers at the point of care. It could change the landscape of how enzyme biomarkers are detected and diagnosed, making an impact not only on food safety, but on the diagnosis of enzyme-related illnesses among animals and humans.
“The potential scope for this test is huge.”
Professor Chris Elliott, founder of the Institute for Global Food Security and a co-investigator in the study commented: “The ability to diagnose disease or contamination quickly can have a huge impact on how serious problems can be dealt with.
“The ultra-low cost of the system will help reduce costs of testing and could transform the amount of testing performed in the developing world.”
The Latest on: Enzyme biomarker
via Google News
The Latest on: Enzyme biomarker
- Anti-Parkinson's Drugs Market Research Based on COVID 19 and Analysis on Techniques and Applications Report 2020-2027on November 20, 2020 at 11:42 am
Nov 20, 2020 (Heraldkeepers) -- Global anti-parkinson's drugs market is segmented based on the product as, Dopaminergic, Dopamine Agonist, and ...
- Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Boardon November 20, 2020 at 3:42 am
Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced the formation of its multi-disciplinary ...
- Avrobio tracks improvements in first patient treated with Gaucher gene therapyon November 17, 2020 at 4:18 am
Avrobio has shared data on the first Gaucher disease patient to receive its gene therapy AVR-RD-02. The patient, who was stable on enzyme replacement therapy at baseline, experienced a 22% drop in a ...
- AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipelineon November 17, 2020 at 4:04 am
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical ...
- CymaBay tees up new phase 3 study for resurrected liver drug as truncated trial shows promiseon November 16, 2020 at 4:04 pm
CymaBay Therapeutics is getting its liver disease drug back on track. The treatment beat placebo at lowering a liver enzyme in patients with primary biliary cholangitis (PBC), a rare, progressive ...
- Metabolic biomarkers could predict COVID-19 severityon November 16, 2020 at 2:42 pm
A new study published on the preprint server medRxiv* in November 2020 discusses the changes in blood metabolites associated with various degrees of COVID-19 severity. The study’s findings suggest ...
- NTHU Researchers Discover New Gastric Cancer Biomarkers for Tailored Therapyon November 13, 2020 at 9:00 am
A research team led by Professor Wang Wen-ching of the Institute of Molecular and Cellular Biology, National Tsing Hua University (NTHU) has exploited ...
- Global Glycomics Market 2020-2026: Rise in Biomarker Discoveries and Emerging Countries Provides Market Opportunitieson November 12, 2020 at 1:11 am
The "Glycomics Market by Product, by Application, by End-User, Geography Forecast Up to 2026" report has been added to ResearchAndMarkets.com's offering. Market is Expected to Reach $2.43 Billion by ...
- Enzyme That Suppresses the Immune Response to Viral Infections Identifiedon November 11, 2020 at 3:01 am
Scientists have discovered how an enzyme that regulates several cellular processes might be a key target to preventing viruses from disarming the human immune response.
- Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle ...on November 10, 2020 at 4:32 am
After four weekly intravenous doses of DNL310, a 76% mean reduction in CSF GAG levels (heparan sulfate) from baseline was observed, with normal healthy levels being achieved in four of five patients ...
via Bing News